Current And Future Market Analysis Of Small Cell Lung Cancer (SCLC) Market 2024: Opportunity and Forecast
"The Latest Research
Report OpportunityAnalyzer: Small Cell Lung Cancer (SCLC) -
Opportunity Analysis and Forecasts to 2024 provides information on
pricing, market analysis, shares, forecast, and company profiles for
key industry participants. - MarketResearchReports.biz"
About
Small Cell Lung Cancer Market
Initially considered a curable
disease due to substantial sensitivity to first-line chemotherapies,
small cell lung cancer (SCLC) remains a fatal disease with poor
outcomes due to high relapse rates, with the majority of patients
surviving one year or less after diagnosis. Unlike non-small cell
lung cancer (NSCLC), in which major advances in treatment have been
made following the approval of several targeted therapies, the field
of SCLC has seen little advancement for several decades.
For the purposes of this report,
GlobalData considers the Global SCLC market to include SCLC-specific
drug sales in the 7MM (US, 5EU [France, Germany Italy, Spain, and the
UK], and Japan). The current market across these countries is
dominated by the sale of major generic chemotherapy regimens.
GlobalData estimated that the Global SCLC market was valued at $198m
in 2014. Following the expected approval of new agents over the
forecast period, relapsed/refractory patients will have significantly
improved therapeutic options leading to rapid uptake of these drugs.
The increased use of branded therapies in treatment-nave and advanced
patients, such as Yervoy, Opdivo, roniciclib, and sacituzumab
govitecan, will be the primary driver of the substantial growth in
the SCLC market over the forecast period, which is expected to grow
at a positive CAGR of almost 28% in the 7MM.
Highlights
Key Questions Answered
-
Based on interviews with key opinion leaders (KOLs), GlobalData has
identified the major unmet needs in the SCLC marketplace. Will the
leading pipeline agents fulfil these unmet needs during the forecast
period (2014-2024)?
Get
Sample copy of this Report @
https://www.marketresearchreports.biz/sample/sample/699490
- What research and development
(R&D) strategies will companies leverage to compete in the future
SCLC marketplace?
- Which pipeline products are
poised to make a major clinical and commercial impact?
- What clinical and commercial
factors are likely to influence SCLC drug uptake in the 7MM?
Key Findings
- The greatest driver of growth
within the Global SCLC market will be the launch and increased use of
premium-priced therapies, including anti-PD-1 immunotherapy and
targeted agents such as roniciclib and sacituzumab govitecan.
GlobalData expects Yervoy to reach blockbuster status by the end of
the forecast period, with global sales of around $1bn.
- Continuous dosing regimens until
disease progression and adoption of maintenance setting following
induction therapy for first-line patients will contribute to the
increased sales of branded drugs.
- Toxicity is likely to remain a
major concern as new first-line treatment options are approved
considering companies are developing them in combination with
platinum-etoposide. Therefore, substantial opportunity remains to
develop therapies that have improved safety profiles compared with
agents in the current SCLC pipeline.
- An increasing emphasis on
cost-consciousness is anticipated over the forecast period, which
will limit premium pricing opportunities for developers of SCLC
pipeline agents. GlobalData expects this era of austerity and
healthcare reform to make it increasingly more difficult for
pharmaceutical companies to gain reimbursement approval for their new
SCLC therapies.
Scope
- Overview of SCLC, including
epidemiology, etiology, pathophysiology, symptoms, diagnosis, and
current treatment options.
- Topline SCLC drug market revenue
from 2014-2024, annual cost of therapy (ACOT), and major product
sales in six patient segments during the forecast period are
included.
- Key topics covered include
strategic competitor assessment, market characterization, unmet
needs, opportunities, R&D strategies, and clinical trial mapping
for the SCLC market.
-
Pipeline analysis: comprehensive data split across different phases,
emerging novel trends under development, synopses of innovative
early-stage projects, and detailed analysis of late-stage pipeline
products. An interactive clinical and commercial analyzer tool is
available.
- Analysis of the current and
future market competition in the global SCLC market. Insightful
review of the key industry drivers, restraints, and challenges. Each
trend is independently researched to provide qualitative analysis of
its implications.
Reasons to buy
The report will enable you to -
- Develop and design your
in-licensing and out-licensing strategies through a review of
pipeline products and technologies, and by identifying the companies
with the most robust pipeline.
- Develop business strategies by
understanding the trends shaping and driving the global SCLC
therapeutics market.
- Drive revenues by understanding
the key trends, innovative products and technologies, market
segments, and companies likely to impact the SCLC market in the
future.
- Formulate effective sales and
marketing strategies by understanding the competitive landscape and
by analyzing the performance of various competitors.
- Identify emerging players with
potentially strong product portfolios and create effective
counter-strategies to gain a competitive advantage.
- Organize your sales and
marketing efforts by identifying the market categories and segments
that present maximum opportunities for consolidations, investments
and strategic partnerships.
Table of Contents
1 Table of Contents 9
1.1 List of Tables 13
1.2 List of Figures 17
2 Introduction 19
2.1 Catalyst 19
2.2 Related Reports 19
2.3 Upcoming Related Reports 20
3 Disease Overview 21
3.1 Etiology and Pathophysiology
21
3.1.1 Etiology 21
3.1.2 Pathophysiology 22
3.2 Symptoms 23
3.3 Diagnosis 24
3.4 Clinical Staging 26
3.5 Prognostic Factors 29
3.6 Quality of Life 29
Send An Enquiry Request @
4 Epidemiology 31
4.1 Disease Background 31
4.2 Risk Factors and Comorbidities
32
4.3 Global Trends 34
4.3.1 Incidence 34
4.3.2 Stage at Diagnosis 34
4.3.3 Relative Survival 34
4.4 Forecast Methodology 35
4.4.1 Sources Used 36
4.4.2 Sources Not Used 42
4.4.3 Forecast Assumptions and
Methods 43
4.5 Epidemiological Forecast for
SCLC (2014-2024) 47
4.5.1 Diagnosed Incident Cases of
SCLC 47
4.5.2 Age-Specific Incident Cases
of SCLC 49
4.5.3 Sex-Specific Incident Cases
of SCLC 51
4.5.4 Age-Standardized Incidence
of SCLC 53
4.5.5 Stage-Specific Incident
Cases of SCLC 54
4.5.6 Five-Year Diagnosed
Prevalent Cases of SCLC 55
4.5.7 Five-Year Diagnosed
Prevalent Cases of SCLC Segmented by Stage 57
4.6 Discussion 58
4.6.1 Epidemiological Forecast
Insight 58
4.6.2 Limitations of the Analysis
60
4.6.3 Strengths of the Analysis 61
5 Current Treatment Options 62
5.1 First-Line Therapy 62
5.2 Second-Line Therapy 68
5.3 Subsequent Lines of Therapy 71
6 Unmet Needs Assessment and
Opportunity Analysis 73
6.1 Overview 73
6.2 Unmet Needs Analysis 74
6.2.1 Early Diagnosis of Disease
74
6.2.2 Therapies That Improve
Overall Survival 76
6.2.3 More Effective and Tolerable
Therapies for Relapsed/Refractory Disease 78
6.2.4 Discovery of Predictive
Biomarkers and Understanding of the Underlying Causes of Disease 79
6.2.5 Smoking Cessation Programs
80
6.3 Opportunity Analysis 81
6.3.1 Standardized Methods for
Biomarker Testing 81
6.3.2 Developing Therapies with an
Improved Safety Profile 82
6.3.3 Understanding the Mechanisms
Underlying the Rapid Emergence of Drug and Radiation Resistance 83
6.3.4 Targeting Pathways Unique to
Cancer Stem Cells 84
7 R&D Strategies 85
7.1 Overview 85
7.1.1 Deconstructing the SCLC
Genome 85
7.1.2 New Diagnostic Approaches 89
7.1.3 Reformulation of Available
Chemotherapeutic Agents 91
7.1.4 Combination Therapy 92
7.2 Clinical Trial Design 93
7.2.1 Evolution of Endpoints for
Cancer Immunotherapy Trials 95
7.2.2 Health-Related Quality of
Life Endpoints in Oncology Clinical Trials 96
7.2.3 Design of Current Phase II
and III Trials in SCLC 97
About us
MarketResearchReports.biz is the
most comprehensive collection of market research reports.
MarketResearchReports.Biz services are specially designed to save
time and money for our clients. We are a one stop solution for all
your research needs, our main offerings are syndicated research
reports, custom research, subscription access and consulting
services. We serve all sizes and types of companies spanning across
various industries.
Contact
Mr. Nachiket
State Tower
90 Sate Street, Suite 700
Albany, NY 12207
Tel: +1-518-621-2074
Comments
Post a Comment